🚀 SpaceX IPO Debrief: The Next 10X Move & the Tesla-SpaceX Arbitrage Play

🎯 The IPO Aftermath: What Happens Next?

With the SpaceX IPO now in the rearview mirror, markets face a critical question: what's the next 10X move? The transcript unpacks the immediate post-IPO dynamics, the structural arbitrage between Tesla and SpaceX, and the longer-term compounding thesis that could reshape portfolios through 2032 and beyond.

SpaceX currently trades at $166.70 in after-hours, with a market cap of $2.2 trillion—precisely in line with pre-IPO projections shared ahead of the listing. Tesla, meanwhile, sits at $164.43, up $26 from $380 just days earlier, reflecting a market cap of $1.5 trillion.

The central thesis: Tesla may be the faster horse over the next six months, while SpaceX represents the longer-duration compounding play into the 2030s.

📊 The Tesla vs. SpaceX Arbitrage Math

A key point of analysis centers on the merger arbitrage opportunity between Tesla and SpaceX. The transcript outlines a structural bet: these two entities will eventually merge, likely around 2027 or 2028, creating a valuation convergence.

"SpaceX has about 13 billion shares outstanding. Tesla has about 3.8 billion. There's a lot more shares for SpaceX. Therefore, more shares, lower price, higher market cap."

This distinction is critical. Share price alone is misleading—outstanding share count determines true valuation. SpaceX's 13.668 billion shares outstanding versus Tesla's 3.69 billion means the per-share price differential does not reflect market cap parity.

Morgan Stanley's 2040 revenue target for SpaceX: $35 trillion, applying a 10x revenue multiple. Meanwhile, Elon Musk has stated that Optimus robots could be worth $25 trillion and robotaxis $5 trillion by 2032—totaling $30 trillion.

The verdict: Tesla is projected to hit its valuation milestones earlier, making it the near-term faster horse. Post-2030, the merged entity becomes the primary thesis.

💰 Millionaire Math: How Many Shares Do You Need?

The transcript provides concrete targets for wealth accumulation through 2032:

• SpaceX: 655 shares to reach $1 million by 2032 (at current post-IPO pricing of $160.95+, this requires approximately $105,000 in capital today)
• Tesla: 323 shares to reach $1 million by 2032 (requiring approximately $131,000 at current levels)

These projections use conservative, sandbagged targets—a 35% CAGR for SpaceX and similar assumptions for Tesla. The longer the holding period, the fewer shares required due to exponential compounding.

"The longer you have in the market, the more you make, especially with exponential assets. The compounding is insane into the future."

For those with a 2036 retirement horizon, the share count could scale down further, leveraging time as the ultimate multiplier.

🤖 Physical AI & Humanoid Robots: Following the Actuators

The discussion shifts to the next massive wave in AI: physical AI and humanoid robots. Morgan Stanley's Humanoid 100 report maps the value chain, but the transcript cautions against overcomplicating the thesis.

Key insight: Actuators represent 60% of total humanoid robot cost, making them the bottleneck in the value chain. Sensing and computer/control systems account for just 10% each.

However, the brutal reality of supply chains applies: the designer and software owner captures the lion's share of profit margins, while component manufacturers face a race to the bottom with heavy capital expenditure constraints.

"Look at Nvidia and TSMC. TSMC is doing well, but Nvidia makes nearly 80% margins. That is the game here."

The parallel with Apple and Foxconn is clear—Tesla is positioned to dominate humanoid robotics through vertical integration and proprietary actuator design, not by relying on a fragmented supply base.

Strategy: Focus on the end winner (Tesla) rather than chasing 100+ supply chain names, many of which are based in China and carry higher risk profiles.

🩺 Intuitive Surgical: A Dabble in Healthcare Robotics

Intuitive Surgical (ISRG) represents a small-allocation, high-conviction play on healthcare robotics. The company commands an 80% market share in robotic surgery via its Da Vinci Systems and has compounded at a 15-20% CAGR historically.

Currently trading around $411.40 with a $146 billion market cap, the stock trades at a 40-50 PE ratio and recently broke below support at $135-$140—a disappointing technical development.

However, the fundamental picture remains intact:

• GuruFocus fair value: $598 (implying 50% upside)
• Wall Street consensus price target: $557 (across 21 analysts, implying 35% upside)
• High target: $672

The thesis: high-margin, strong moat, significantly undervalued. Risks include tariff impacts, elective surgery trends, and competition from Medtronic and Johnson & Johnson. If the stock reaches the low $400s or $380 range, it becomes a potential double- or triple-down opportunity.

"If we do get to the low 400s, I might double down or triple down. We'll see."

⏳ Timing SpaceX Entry: The Indicator Problem

A structural challenge for new IPOs: technical indicators require historical data to generate signals. IDSS, ATR levels, and moving averages need time to populate.

Timeline for indicator reliability:

• 5-minute charts: Start working after 1-2 weeks
• 50-day moving average: Fires after 50 trading days
• 100-day indicators: Become robust after 100 days
• 200-day moving average: Full signal reliability after 200 days

IPOs typically experience a dip 60-90 days post-listing due to lock-up expirations and profit-taking. For SpaceX, a 20% drawdown from current levels (targeting $135-$141) would present a high-conviction entry point.

Rule: Avoid chasing green candles. Wait for aggressive dips and consider dollar-cost averaging into weakness.

🪙 Solana & the Crypto Bleed: Hold or Rotate?

The Solana ecosystem has been "absolutely bled out," with core Solana alts like Orca, Raydium, and Jupiter all retracing to pre-hype levels despite strong fundamentals.

Current pricing:

• Orca: $1.10
• Raydium: $0.59
• Jupiter: $0.17 (down from entries at $0.35-$0.50)

Despite the drawdown, Solana's fundamentals remain incredibly strong:

• 4,000% more daily transactions than Ethereum
• 550% more daily active users than Ethereum
• Yet Ethereum trades at over 5x Solana's valuation

The core issue: DEXs face a race-to-the-bottom dynamic as fee competition intensifies. Revenue models that worked historically may not persist.

Strategy: If positions have shrunk to "crumbs," rotating them may not be worth the tax or trading friction. Hold and wait for the next crypto cycle, contingent on agentic adoption driving a billion daily users to Solana.

💎 Solana Treasury Proxies: Deep Discounts Persist

For exposure to Solana via public equities, treasury proxies offer leveraged upside—but only if Solana recovers.

Current NAV discounts:

• UPXI: Trading at 44 cents on the dollar
• HSDT: 65 cents on the dollar
• DeFi Dev: 62 cents on the dollar
• Forward Industries: 67 cents on the dollar
• Stake: Trading at a premium (avoid)

All hold approximately 2 million SOL (except Forward Industries at 7 million and Stake at 533,000). These proxies will amplify Solana's recovery—if it materializes.

🎯 Tesla Synthetic Longs & Margin Strategy

The transcript details an aggressive play: selling Tesla puts to fund synthetic long exposure via deep-in-the-money LEAPS, using seven-figure margin to amplify positioning at the bottom.

"I yoloed into those Tesla LEAPs, but it cost me a lot in margin, deep into seven digits in margin to do this."

Why it worked: The SpaceX IPO created a liquidity drain that temporarily depressed Tesla. Once investors realized they wouldn't receive SpaceX allocations, capital flowed back into Tesla, driving the $26 rebound in days.

Critical warnings:

• Only execute synthetic longs at bottoms
• Never use more than 20% of available margin
• Margin is a double-edged sword—black swan events can trigger liquidation
• This strategy is not suitable for portfolios without "oodles of margin"

Translation: Don't try this at home.

🐾 Channel Proceeds: Supporting Animal Welfare

This week's channel proceeds were donated to Sunrise Rescue, supporting critical animal well-being initiatives and veterinary care for animals in need.

✅ Final Takeaways

• SpaceX: Currently at $166.70, targeting $135-$141 for high-conviction entry; 655 shares = $1M by 2032
• Tesla: The faster horse near-term; 323 shares = $1M by 2032
• Humanoid robots: Follow the actuators, but bet on the end designer (Tesla)
• Intuitive Surgical: 50% undervalued at $411; watch for dips to low $400s
• Solana: Fundamentally strong, but needs adoption catalyst to reverse bleed
• Margin plays: High-risk, high-reward—only for those with deep liquidity buffers

Not financial advice. All analysis reflects personal positioning and risk tolerance.